Clarify Health

JANUARY 26, 2022

It is a real-world evidence-based software product that empowers life sciences companies to improve the recruitment of diverse and underrepresented patient populations. These data are linked to government and commercial claims, clinical, prescription and dispensing data, covering over 300 million patient lives.

Recruitment 52

Recruitment Transportation Physicians Education 52

PM360

MARCH 28, 2023

The Healthcare Businesswomen’s Association (HBA) has appointed Mary Stutts as Chief Executive Officer where she will lead the global association’s mission to accelerate the advancement and impact of women in the business of healthcare. Most recently, Stutts served as Chief Global Health Equity and Inclusion Officer for Real Chemistry.

Healthcare 52

Healthcare Healthcare Biopharma Leads 52

pharmaphorum

SEPTEMBER 28, 2022

Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program at the National Institutes of Health (NIH), tells pharmaphorum about the programme and how it will accelerate research for the benefit of all patients. Gathering data.

Medicine 90

Medicine Food and Drug Administration Medical FDA 90

Pharma Marketing Network

MARCH 30, 2023

Mary brings to the HBA 30 years of experience leading the strategic integration of corporate branding, marketing, health equity, inclusion, and digital innovation for biopharma, healthcare, and media companies. Most recently, Stutts served as Chief Global Health Equity and Inclusion Officer for Real Chemistry.

Healthcare 52

Healthcare Healthcare Biopharma Networking 52

PM360

SEPTEMBER 7, 2023

Since 2020, diversity, equity, and inclusion (DE&I) has been a prime area of attention within healthcare and the life sciences. For one, the pandemic put a spotlight on the disparity within clinical trials—in 2020 the FDA found that 75% of trial participants were white, 11% were Hispanic, 8% were Black, and 6% were Asian.

Healthcare 111

Healthcare Healthcare Patients Education 111

Clarify Health

DECEMBER 6, 2021

Greater clinical trial diversity, better disease education, and innovative assistance programs are a few ways that pharma companies are supporting and including underserved and more vulnerable patient groups. They discussed barriers to Diversity and Inclusion (D&I) and how we can accelerate the pace of change.

Pharma 52

Pharma Patients Recruitment Physicians 52

Clarify Health

MAY 27, 2022

The FDA’s latest draft guidance on diversity and inclusion in clinical trials Diversity within the US continues to grow, with four in 10 Americans identifying with a race or ethnic group other than white. Data from clinical trials provide the basis for evaluating whether a medical product is safe and effective.

FDA 52

FDA Food and Drug Administration Recruitment Transportation 52